Apoptosis/Cell Death, Autophagy, Cardiovascular, Cellular Differentiation, Diabetes, Electrophysiology, Fibrosis, Gene Expressions, Gene Regulation, Gene Therapy, Human Genetics and Genetic Disorders, IGF-1 Receptor, Insulin, Insulin Receptor, Lipid Signaling, Liver, Membrane Proteins/Channels, Microarray, Mitochondria, Muscle Cells, Muscular Dystrophy, Obesity, Oxidative Phosphorylation, Oxidative Stress, Proteomics, Receptors, Signal Transduction, Stem Cells, Transcription Factors, Transgenic Mice
Multi-Disciplinary Training Area
Biophysics and Systems Pharmacology [BSP]
Kang S, Dahl R, Hsieh W, Shin A, Zsebo K, Buettner C, Hajjar R, Lebeche D. Small Molecular Allosteric Activator of the Sarco/Endoplasmic Reticulum Ca2+-ATPase (SERCA) Attenuates Diabetes and Metabolic Disorders.. J Biol Chem 2016 March; 291(10): 5185-98.
Tong X, Kono T, Anderson-Baucum E, Yamamoto W, Gilon P, Lebeche D, Day R, Shull G, Evans-Molina C. SERCA2 Deficiency Impairs Pancreatic β-Cell Function in Response to Diet-Induced Obesity. . Diabetes 2016 October; 65(10): 3039-52.
Lebeche D. Diabetic cardiomyopathy: is resistin a culprit?. Cardiovasc Diagn Ther. 2015 Oct; 5(5): 387-93.
Ramos-Kuri M, Rapti K, Mehel H, Zhang S, Dhandapany P, Liang L, Garcia-Carranca A, Bobe R, Fischmeister R, Adnot S, Lebeche D, Hajjar R, Lipskaia L, Chemaly E. Dominant negative Ras attenuates pathological ventricular remodeling in pressure overload cardiac hypertrophy.. Biochim Biophys Acta 2015 Nov; 1853(11PtA): 2870-84.
Cai W, Liu G, Lam C, Florea S, Qian J, Zhao W, Pritchard T, Haghighi K, Lebeche D, Lu L, Deng J, Fan G, Hajjar R, Kranias E. Up-regulation of micro-RNA765 in human failing hearts is associated with post-transcriptional regulation of protein phosphatase inhibitor-1 and depressed contractility.. Eur J Heart Fail 2015 Aug; 17(8): 782-93.
Dhandapany P, Razzaque M, Muthusami U, Kunnoth S, Edwards J, Mulero-Navarro S, Riess I, Pardo S, Sheng J, Rani D, Rani B, Govindaraj P, Flex E, Yokota T, Furutani M, Nishizawa T, Nakanishi T, Robbins J, Limongelli G, Hajjar R, Bahl A, Khullar M, Rathinavel A, Sadler K, Tartaglia M, Matsuoka R, Thangaraj K, Gelb B, Lebeche D. RAF1 mutations in childhood-onset dilated cardiomyopathy. Nat Genet 2014 Jun; 46(6): 635-9.
Wei Y, Peng S, Wu M, Sachidanandam R, Tu Z, Zhang S, Falce C, Sobie EA, Lebeche D, Zhao Y. Multifaceted roles of miR-1s in repressing the fetal gene program in the heart. Cell research 2014 Mar; 24(3).
Chemaly ER, Kang S, Zhang S, McCollum L, Chen J, Bénard L, Purushothaman KR, Hajjar RJ, Lebeche D. Differential patterns of replacement and reactive fibrosis in pressure and volume overload are related to the propensity for ischaemia and involve resistin. The Journal of physiology 2013 Nov; 591(Pt 21).
Karakikes I, Chaanine AH, Kang S, Mukete BN, Jeong D, Zhang S, Hajjar RJ, Lebeche D. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. Journal of the American Heart Association 2013 Apr; 2(2).
Kang S, Lebeche D. Myocardial calcium signaling in physiology and disease. Journal of Receptor, Ligand and Channel Research 2013; 6: 1-13.
LaRocca TJ, Fabris F, Chen J, Benhayon D, Zhang S, McCollum L, Schecter AD, Cheung JY, Sobie EA, Hajjar RJ, Lebeche D. Na+/Ca2+ exchanger-1 protects against systolic failure in the Akitains2 model of diabetic cardiomyopathy via a CXCR4/NF-κB pathway. American journal of physiology. Heart and circulatory physiology 2012 Aug; 303(3).
Balderman JA, Lee HY, Mahoney CE, Handy DE, White K, Annis S, Lebeche D, Hajjar RJ, Loscalzo J, Leopold JA. Bone morphogenetic protein-2 decreases microRNA-30b and microRNA-30c to promote vascular smooth muscle cell calcification. Journal of the American Heart Association 2012 Dec; 1(6).
Chemaly ER, Hadri L, Zhang S, Kim M, Kohlbrenner E, Sheng J, Liang L, Chen J, K-Raman P, Hajjar RJ, Lebeche D. Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats. Journal of molecular and cellular cardiology 2011 Aug; 51(2).
Kang S, Chemaly ER, Hajjar RJ, Lebeche D. Resistin promotes cardiac hypertrophy via the AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) and c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathways. The Journal of biological chemistry 2011 May; 286(21).
Dhandapany PS, Fabris F, Tonk R, Illaste A, Karakikes I, Sorourian M, Sheng J, Hajjar RJ, Tartaglia M, Sobie EA, Lebeche D, Gelb BD. Cyclosporine attenuates cardiomyocyte hypertrophy induced by RAF1 mutants in Noonan and LEOPARD syndromes. Journal of molecular and cellular cardiology 2011 Jul; 51(1).
Dobrin JS, Lebeche D. Diabetic cardiomyopathy: signaling defects and therapeutic approaches. Expert review of cardiovascular therapy 2010 Mar; 8(3).
Jin H, Hadri L, Palomeque J, Morel C, Karakikes I, Kaprielian R, Hajjar R, Lebeche D. KChIP2 attenuates cardiac hypertrophy through regulation of Ito and intracellular calcium signaling. Journal of molecular and cellular cardiology 2010 Jun; 48(6).
Karakikes I, Kim M, Hadri L, Sakata S, Sun Y, Zhang W, Chemaly ER, Hajjar RJ, Lebeche D. Gene remodeling in type 2 diabetic cardiomyopathy and its phenotypic rescue with SERCA2a. PloS one 2009; 4(7).
Lebeche D, Davidoff AJ, Hajjar RJ. Interplay between impaired calcium regulation and insulin signaling abnormalities in diabetic cardiomyopathy. Nature clinical practice. Cardiovascular medicine 2008 Nov; 5(11).
Kim M, Oh JK, Sakata S, Liang I, Park W, Hajjar RJ, Lebeche D. Role of resistin in cardiac contractility and hypertrophy. Journal of molecular and cellular cardiology 2008 Aug; 45(2).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Lebeche did not report having any of the following types of financial relationships with industry during 2016 and/or 2017: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.